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The new US President will be selecting the next director of the National Institutes of Health (NIH) 
at a time when the agency faces many challenges. Priorities for the new director include boosting 
the NIH coffers in troubled economic times, balancing funding for basic and translational research, 
and helping young scientists.By the time you are reading this article, 
Americans will have elected their next 
President. The choice of presidential 
candidate will have a huge impact on 
scientific research in the US, from the 
amount of money allocated to it, to how 
that money can be used. Among the 
many tasks facing the new President 
(who will take office on January 20, 2009) 
will be to choose the next director of the 
National Institutes of Health (NIH), the 
largest government-funding agency for 
biomedical research in the US.
Elias Zerhouni, the 15th NIH director 
(see Box 1), presided over the $29 bil-
lion agency for 6 years and left his post 
last month to pursue writing projects 
and other “professional opportunities.” 
Perhaps the biggest defining feature of 
Zerhouni’s tenure, since his appoint-
ment as NIH director in May 2002, was a 
budget that failed to keep up with infla-
tion (http://www.nih.gov/about/almanac/
appropriations/part2.htm). Having dou-
bled from $13.6 billion in 1998 to $27 bil-
lion in 2003, the NIH budget only enjoyed 
modest increases since then ($27.9 bil-
lion in 2004, $28.5 billion in 2005 and 
2006, and $29 billion in 2007)—in fact, 
it actually decreased, if inflation is taken 
into account (see Figure 1).
The budget will undoubtedly be one 
of the biggest challenges facing the 
new NIH director. But there are other 
considerations, including juggling pri-
orities such as basic versus translational 
research and big science versus small 
science, and addressing the needs of 
the next generation of scientists.
Science’s Advocate on the Hill
The next NIH director will also have to 
convince a now worried US Congress 
facing tough economic issues of the 
value of the research funded by NIH. 
Harold Varmus, who held the reins of 
NIH from 1993 to 1999 during better eco-nomic times in the Clinton administration 
(see Box 1), proved particularly adept 
at this task. He built strong support in 
the US Congress for scientific research, 
resulting in a generous increase in the 
NIH budget from just over $10 billion to 
almost $16 billion during his tenure.
“The major challenge of the new NIH 
director will be having to convince Con-
gress of the value of fundamental basic 
research,” says Sandra Schmid, chair of 
the Department of Cell Biology at The 
Scripps Research Institute in La Jolla, 
California. “The new director has to 
explain how NIH sits in the perspective 
of the entire system of medical research, 
medical discovery, and human health,” 
she continues. “NIH is not an isolated 
enterprise. It impacts on everything in the 
entire research and development system. 
The NIH director has to explain to the 
American people that it’s the NIH engine 
that totally turns the motor of the biotech-
nology and pharmaceutical industry.”
“I can only hope that the new admin-
istrator and director are progressive Cell 135, Nenough that they can make the case 
that the future of science and technol-
ogy in this country is really dependent 
on federal funding,” says Robert Tjian, 
a molecular biologist at the Univer-
sity of California, Berkeley, who will 
become the next president of the How-
ard Hughes Medical Institute (HHMI) in 
April 2009. “It is critical that the new 
director really understands the value of 
basic research and can articulate that 
very clearly to Congress. I am not sure 
that in recent years that has been done 
as effectively as it should have been,” 
Tjian says.
Ballooning Costs and Shrinking 
Paylines
Since 2003, the NIH budget has remained 
essentially flat, but the number of 
researchers and cost of doing research 
have increased. As a result, the number 
of applications for R01 individual investi-
gator grants has also increased, result-
ing in a steady decline in “paylines.” Pay-
lines are funding cut-off points that the Figure 1. NIH Budget by Institute, 1998–2009
Amounts in billions of constant FY 2008 dollars were calculated by converting actual dollar amounts 
for a particular year to the dollar value in 2008. The 2009 figures are the latest estimates of 2009 Sen-
ate appropriations according to the American Association for the Advancement of Science (AAAS R&D 
reports). NIAID, National Institute of Allergy and Infectious Diseases; NHLBI, National Heart, Lung and 
Blood Institute; NCI, National Cancer Institute.ovember 14, 2008 ©2008 Elsevier Inc. 583
Box 1. A History of NIH Directors
1887: A bacteriological laboratory, known as the Laboratory of Hygiene, was established under  Joseph 
J. Kinyoun at the Marine Hospital, Staten Island, NY in August
1891: The Laboratory of Hygiene (renamed Hygienic Laboratory) moved from Staten Island to 
 Washington DC in June.
1899: On May 1 Milton J. Rosenau succeeded Dr. Kinyoun as director of the Hygienic Laboratory.
1909: John F. Anderson was appointed Hygienic Laboratory director on October 1.
1915: George W. McCoy was appointed Hygienic Laboratory director on November 20.
1930: On May 26 the Ransdell Act redesignated the Hygienic Laboratory as the National Institutes of 
Health (NIH).
1936: On August 10, Mr. and Mrs. Luke I. Wilson made the first of several gifts of land from their estate 
for use by NIH in Bethesda, MD.
1937: Lewis R. Thompson was appointed NIH director on February 1.
1942: Rolla Eugene Dyer was appointed NIH director on February 1.
1950: William H. Sebrell, Jr. was appointed NIH director on October 1.
1955: James A. Shannon was appointed NIH director on August 1.
1968: Robert Q. Marston was sworn in as NIH director on August 29.
1973: Robert S. Stone was sworn in as the 10th NIH director on May 29.
1975: Donald S. Fredrickson was sworn in as the 11th NIH director on July 1.
1981: On June 30, Fredrickson stepped down and Thomas E. Malone was appointed acting director.
1982: James B. Wyngaarden, chairman of the Duke University Department of Medicine, was ap-
pointed NIH director on April 29.
1991: Bernadine Healy was confirmed as NIH’s 13th director on March 21, the first woman to be ap-
pointed to this post.
1993: Healy stepped down, and Harold Varmus was appointed NIH’s 14th Director by President Clin-
ton. Varmus was the first Nobel Laureate to be appointed NIH director.
1999: After leading NIH for 6 years, Varmus left to become the President and CEO of Memorial Sloan-
Kettering Cancer Center in New York City.
2000: On January 1, Ruth Kirschstein, deputy director of NIH, became the acting director.
2002: In May, Elias Zerhouni became the 15th director of the NIH.
2008: Zerhouni steps down in October, and deputy NIH director, Raynard Kington, becomes acting 
director.different NIH institutes set at the start 
of the fiscal year in order to balance the 
estimated number of grant applications 
expected to be recommended for fund-
ing with the money available to spend. In 
2008, paylines for R01 grants were 14% 
for the National Cancer Institute and 12% 
for the National Institute of Allergy and 
Infectious Diseases (NIAID). (NIAID pay-
lines for 2009 are projected to be even 
lower at 10%; http://www.niaid.nih.gov/
ncn/budget/budg-paylines.htm.)
Many researchers feel that the current 
cut-off points for funding are too low for 
the grant peer review system to work. 
“When only the top 10% of grants are 
funded, decisions for funding become 
somewhat random. It is very hard to dis-
tinguish between the top 10% versus the 
top 20%,” says Kornelia Polyak, an asso-
ciate professor at the Dana-Farber Can-
cer Institute and Harvard Medical School 
in Boston. “Having paylines above 20% 
removes this randomness.”
“The top priority is to get paylines for 
R01s to 25%–30% to ensure that the 
best investigators are getting funded. 
That is the bread and butter for bio-
medical research,” says cardiologist 
Andrew Marks, chairman of the Physi-
ology Department at Columbia Univer-584 Cell 135, November 14, 2008 ©2008 Elssity in New York City. “If the paylines 
are low the system breaks down. It 
becomes arbitrary what research gets 
funded.”
Zerhouni took steps during his tenure 
to streamline the grant peer review sys-
tem, releasing, in September, proposed 
changes to reduce the burden on review-
ers and to ensure more even-handed 
review of grant applications (Cell 135, p. 
201, 2008). Says Marks, “the peer review 
system can certainly be improved, but it 
has natural limitations because it is run 
by researchers. You have to get paylines 
up to a level where reviewers can recom-
mend funding most of the grants that are 
proposing good research.”
Weights and Measures
A big challenge for the next NIH director 
will be to balance a portfolio of many dif-
ferent priorities. “Scientists are excellent 
at measuring things. That is what we do,” 
says cancer researcher Bert Vogelstein, 
HHMI Investigator and director of the Lud-
wig Center at the Kimmel Comprehensive 
Cancer Center at Johns Hopkins in Balti-
more, Maryland. “We can measure things 
down to Angstroms, but have not devised a 
way to measure the productivity achieved 
through grants. Is it better to fund projects evier Inc.through centers of excellence or R01s, 
consortia or individual grants, NIH intra-
mural or extramural research? Many of the 
current granting mechanisms came into 
being for good reasons—others for politi-
cal reasons. Going forward it is essential 
to have some way of measuring which of 
these types of grants produces the big-
gest bang for the buck.”
A particularly tough challenge for the 
next NIH director will be to balance the 
value of “big science,” typically con-
ducted by a large group of collaborative 
labs or consortia working within a some-
what rigorous framework, against the 
importance of “small science,” carried 
out by individual investigators follow-
ing their own ideas. “Some of the larger 
projects are worthwhile, but what is the 
balance?” says Tjian. “The problem is 
that funding a consortium in a particular 
area takes away money from R01s. This 
problem then gets exacerbated when 
the paylines for R01 grants are 10% or 
less.”
A group of scientists recently wrote a 
letter (Science 322, p. 43, 2008) criticiz-
ing the value of the Epigenomics Road-
map, a large coordinated effort to cata-
log epigenetic modifications across the 
whole human genome. The initiative is 
funded by NIH to the tune of $190 mil-
lion, an amount that could support 200 
R01 grants. “The epigenetics field is very 
exciting and there are plenty of people 
doing good work here. But a consor-
tium is a poor choice for a fast-moving 
field, especially without a clear rationale 
for why a consortium is needed,” says 
molecular biologist Kevin Struhl of Har-
vard Medical School, one of the indi-
viduals who signed the Science letter. 
According to Struhl and his colleagues, 
“merely cataloging modification patterns 
offers relatively little new or useful infor-
mation.”
The Roadmap initiatives, launched by 
Zerhouni in 2002, are aimed at address-
ing “critical roadblocks and knowledge 
gaps that currently constrain rapid prog-
ress in biomedical research.” Funding 
for Roadmap initiatives grew from $132 
million in 2004 to $520 million in 2008, 
and another $500 million is committed 
for 2009. Many scientists have criticized 
the Roadmap initiatives for diverting 
much-needed resources from individual 
investigator R01 grants. “The historical 
power of NIH is to let researchers decide 
what is the best thing rather than having 
NIH direct how to do experiments,” says 
Struhl.
The next NIH director will have to 
decide not only how much NIH should 
“direct” science but also how it can 
achieve the right balance between sup-
porting basic science versus transla-
tional and clinical research. “We need 
someone who has a lot of credibility 
with scientists and who understands 
the deep value of basic research,” says 
Tjian. “The ultimate goal of NIH is trans-
lational research but many of those dis-
coveries are rooted in basic research,” 
he says.
At the same time, others point out 
that translational research will not hap-
pen without targeted support from NIH. 
“Basic science is critical, but NIH also has 
an obligation to make sure that discover-
ies that come forward from basic science 
are translated to treatments to help human 
beings,” says Pamela Davis, dean and vice 
president for medical affairs at Case West-
ern Reserve University in Ohio. Last year, 
the university received a $64 million grant 
as part of NIH’s Clinical and Translational 
Science Award, another Roadmap initia-
tive. “Clinical investigators are an endan-
gered species—there are fewer of them 
and they are emerging later in life,” says 
Davis. “With a budget that is not adequate 
to do everything, the new NIH director will 
have to make sure to continue to support 
great discoveries from basic research, but 
also provide the right infrastructure to sup-
port translational research.”
Many scientists, however, worry that a 
combination of research projects whose 
scope is directed by NIH through Road-
map priorities together with low paylines 
for independent research grants are sti-
fling innovation and risk taking by scien-
tists. “You basically cannot do risky sci-
ence. If you propose a cool idea but do not have enough preliminary data, it will 
not get funded. It has to be guaranteed 
to work,” says Struhl. “Anything that has 
a minor flaw, unless it is aligned with a 
special program, will not get funded,” he 
emphasizes.
“We have gotten to the point where the 
ability to accomplish a project weighs 
most heavily in the decision for funding. 
The thing that has any chance of getting 
funded through regular NIH grants is 
“evolutionary” research rather than “rev-
olutionary” research,” says Vogelstein. 
“The next NIH director will have to decide 
what mixture of evolutionary and revolu-
tionary is best.” 
The NIH Director’s Pioneer and New 
Innovator Awards launched by Zerhouni 
do fund high-risk research projects with 
many awardees being early career sci-
entists, but the program is still small (this 
year, 47 researchers will be awarded $1.5 
to $2.5 million each over 5 years). The 
recently created “transformative” R01 
awards are also focused on risky proj-
ects, although again the total number of 
these awards has been modest.
Looking to the Next Generation
A pressing priority for the next NIH direc-
tor will be to address the needs of young 
scientists. After spending a minimum of 
8 to 10 years training to be independent 
scientists, postdocs discover that only a 
minority of them will be able to land fac-
ulty positions in academia.
“I think there is a lot of fear and worry 
in the postdoc community and it has 
been here for a long time now,” says Alex 
Palazzo, a postdoc at Harvard Medical 
School, who shares his views on his blog 
The Daily Transcript (http://scienceblogs.
com/transcript). “It used to be that a 
postdoc was a two-year apprenticeship 
for a job. Now we spend a lot of hours 
doing risky projects and only 10% of us 
are getting faculty jobs. I hope that the Cell 135, Nnext NIH director takes a serious look 
at the pipeline for scientific research 
careers.”
Part of the problem is that the number 
of postdocs in the US has been growing 
at a rate that is not sustainable. When 
NIH underwent a doubling of its budget 
from 1998 to 2003, there were more suc-
cessful grant applications, more PhDs 
were awarded, and more foreign scien-
tists came to the US, all resulting in a 
big boost in the number of postdoctoral 
positions.
“The whole system has to be rethought 
because the current state of affairs is not 
sustainable,” says Palazzo. Rethinking 
the whole system will require “looking 
at developing research associate posi-
tions, staff scientists, and other oppor-
tunities for postdocs,” suggests Schmid. 
“We can continue to train just as many or 
more PhDs, but right now we are losing 
that talent pool. We are putting everyone 
on the default pathway of postdoc and 
not managing our talent effectively,” she 
says.
The scientist selected to be the next 
NIH director undoubtedly will need to 
make tough and unpopular decisions and 
will need to develop creative ways to bal-
ance a number of pressing priorities in a 
tough economic climate. The next NIH 
director must be able to communicate 
these decisions not only to scientists but 
also to the Congress and the American 
public and convince them of the value of 
the research that NIH funds. He or she 
will also need to be someone who can 
motivate young researchers to continue 
on their chosen career paths. “There 
are people like that out there, who have 
that kind of vision,” says Tjian, “who are 
capable of progressive thinking and have 
a great reputation among scientists.” And 
if the new US President is reading this 
article, he hopefully will have the vision to 
find someone like that to lead NIH.
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